S2 Genomics
S2 Genomics, headquartered in Livermore, CA, specializes in automated tissue dissociation systems, offering the Singulator™ Platform for processing various tissue types into single cells or nuclei suspensions for genomic and cell biology applications.
Company Overview
S2 Genomics is a biotechnology firm headquartered in Livermore, CA, specializing in the development of automated tissue dissociation systems. The company focuses on providing advanced solutions for single-cell and genomic analyses through its innovative products and platforms.
Singulator™ Platform
The Singulator™ Platform by S2 Genomics is an automated tissue dissociation system capable of processing solid tissues into single cells or nuclei suspensions. This platform supports a variety of applications, including ultra-low volume nuclei isolations from just 500 μl of NIR, and the isolation of nuclei from FFPE tissue samples, enabling snRNA-Seq for FFPE samples. The Singulator™ 100 System can process fresh, frozen, OCT, and FFPE tissues to produce high yields from small samples.
Products
S2 Genomics offers a range of specialized products, including the Singulator™ Platform, the NIC+ Small Sample Cartridge, and the Nuclei Debris Removal Stock Reagent. These products cater to various applications in genomics, cell biology, and other 'omics fields, such as scRNA-Seq, snRNA-Seq, ATAC-Seq, CITE-Seq, FACS, and immuno-oncology.
Funding and Partnerships
In January 2024, S2 Genomics raised a Series A funding round led by BroadOak Capital Partners and RCT. The company has entered into key distribution agreements with Bonsailab for the Iberian Peninsula, Proteigene in France, Techtum Lab AB for Scandinavia, and Eisenberg for Israel. Additionally, S2 Genomics collaborates with companies like Parse Biosciences, Dolomite Bio, Applied Cells, and Mission Bio.
Research and Development Facilities
S2 Genomics operates out of Livermore, CA, where it maintains well-equipped laboratories focused on instrumentation development, molecular biology, cell biology, and genomics. These facilities support the company's commitment to innovation and the advancement of tissue dissociation technologies.